Company Profile

Humanigen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing its portfolio of proprietary Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. Its product candidate, lenzilumab, and its other product candidate, ifabotuzumab (iFab), are Humaneered monoclonal antibodies are Humaneered monoclonal antibodies. lenzilumab is used as a therapeutic for chronic myelomonocytic leukemia; for the prevention of acute graft versus host disease; and as a prophylactic companion for certain chimeric antigen receptor therapy (CAR-T) programs. The Company has developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to optimize them.

Employees

Sector

Pharmaceuticals

More about the company

12/07/24	Humanigen, Inc. Went Out of Business	CI
18/06/24	Third Modified Combined Liquidation Plan Approved for Humanigen, Inc.	CI

12/07/24	Humanigen, Inc. Went Out of Business	CI
18/06/24	Third Modified Combined Liquidation Plan Approved for Humanigen, Inc.	CI
01/05/24	Combined Hearing for Disclosure Statement and Plan Approved for Humanigen, Inc.	CI
12/04/24	Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc.	CI
08/03/24	Final DIP Financing Approved for Humanigen, Inc.	CI
17/02/24	Motion for Asset Sale Approved for Humanigen, Inc.	CI
13/02/24	Notice for Auction Cancellation Filed by Humanigen, Inc.	CI
25/01/24	Bidding Procedure Approved for Humanigen, Inc.	CI
08/01/24	Taran Therapeutics, Inc. agreed to acquire Assets of Humanigen, Inc. for $20 million.	CI
05/01/24	19 treatment developer Humanigen files for Chapter 11 bankruptcy	RE
04/01/24	Motion for Asset Sale Filed by Humanigen, Inc.	CI
03/01/24	Humanigen, Inc. Filed for Bankruptcy	CI
03/01/24	Interim DIP Financing Approved for Humanigen, Inc.	CI

11/01/23	Cantor Fitzgerald Reinstates Humanigen at Neutral With $0.15 Price Target	MT
13/07/22	Roth Capital Partners Downgrades Humanigen to Neutral From Buy, Sets Price Target to $2 From $13	MT
13/07/22	HC Wainwright Downgrades Humanigen to Neutral from Buy	MT
13/07/22	Cantor Fitzgerald Downgrades Humanigen to Neutral From Overweight, Adjusts Price Target to $2 From 30	MT
14/02/22	Credit Suisse Lowers Humanigen's Price Target to $3 from $6, Maintains Neutral Rating	MT

12-17	Humanetics Corporation Appoints Timothy E. Morris as Chief Operating Officer	AQ
31/07/24	Implementing 10b5-1 Trading Plans After SEC Amendments And Peizer - July 2024	AQ
09/08/23	CapitalGainesReport: OTC Bounce List (EPAZ, ABML, HGEN, RINO)	AQ
19/07/23	Exploring Breakthrough Biotech Stocks: ENZC, CYDY, HGEN, HALB	AQ
19/04/23	HUMANIGEN, INC : Other Events, Financial Statements and Exhibits (form 8-K)	AQ

04/10/22	DBV Technologies : nouveau président du comité d'audit
18/06/22	Humanigen conclut un accord avec PCI Pharma Services dans le cadre des préparatifs de commercialisation au Royaume-Uni
18/06/22	Humanigen trifft eine Vereinbarung mit PCI Pharma Services als Teil der Vorbereitungen für die Vermarktung im Vereinigten Königreich
20/04/22	Humanigen kündigt Veröffentlichung an, die von Experten begutachtet wurde und die potenziellen klinischen und wirtschaftlichen Vorteile von Lenzilumab aus Sicht des NHS darlegt
20/04/22	Humanigen annonce une publication évaluée par des pairs, qui démontre les avantages cliniques et économiques potentiels du lenzilumab du point de vue du NHS

KaloBios Pharmaceuticals Inc Stock Nasdaq

Stocks

US48344T2096

Pharmaceuticals

Latest news: KaloBios Pharmaceuticals Inc

Analysts' recommendations: KaloBios Pharmaceuticals Inc

Press Releases: KaloBios Pharmaceuticals Inc

News in other languages: KaloBios Pharmaceuticals Inc

Managers and Directors: KaloBios Pharmaceuticals Inc

Biopharmaceuticals

Company Profile

Manager	Title	Age	Since
Cameron Durrant CEO	Chief Executive Officer	65	01/03/2016
Dale Chappell CTO	Chief Tech/Sci/R&D Officer	55	06/07/2020
Bob Atwill PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Cameron Durrant CHM	Chairman	65	07/01/2016
Dale Chappell BRD	Director/Board Member	55	05/02/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.62%	-0.10%	+50.70%	+114.07%	1,031B
JOHNSON & JOHNSON	-2.30%	-3.90%	+39.50%	+66.07%	638B
ABBVIE INC.	-0.63%	-1.94%	+12.26%	+74.38%	462B
MERCK & CO., INC.	-1.03%	-2.88%	+71.35%	+39.69%	359B
ROCHE HOLDING AG	-0.03%	-3.91%	+34.28%	+39.35%	335B
NOVARTIS AG	-1.58%	+0.39%	+17.92%	+25.77%	273B
ASTRAZENECA PLC	-2.02%	-3.20%	+7.60%	+8.38%	253B
AMGEN INC.	-3.38%	+0.29%	+44.32%	+51.54%	228B
GILEAD SCIENCES, INC.	-1.04%	-2.56%	+32.88%	+96.82%	185B
Average	-0.66%	-0.36%	+34.53%	+57.34%	418.21B
Weighted average by Cap.	-0.24%	-0.35%	+38.05%	+69.18%

End-of-day quote Nasdaq
- ^USD	-